Resumen

ARCOS HERNANDEZ, Héctor; GONZALEZ ALDECO, Pablo Mariano  y  CORONA, Ricardo Pablo. Serum magnesium levels in pregnant patients with hypertensive disease managed with magnesium sulfate. Acta méd. Grupo Ángeles [online]. 2020, vol.18, n.2, pp.172-176.  Epub 28-Mar-2022. ISSN 1870-7203.  https://doi.org/10.35366/93891.

Eclampsia occurs in 2 to 3% of women with preeclampsia with non-seizure prophylaxis, and up to 0.6% of women with preeclampsia without severity criteria. A therapeutic range of 4.8 to 8.4 mg/dL is recommended according to retrospective information. An observational, retrospective and descriptive study was conducted, taking as a sample those patients who have had hypertensive pregnancy disease with indication for the administration of magnesium sulfate as anticonvulsant prophylaxis, with impregnation dose with 4 g intravenous and 1 g/h maintenance with magnesium sulfate. A retrospective study was conducted in patients diagnosed with pregnancy-induced hypertensive disease who required treatment with magnesium sulfate as anticonvulsant prophylaxis and those who had taken serum magnesium levels, those which were later analyzed. Of the 66 patients treated with magnesium sulfate, 56 patients (84.4%) were found to have been in infratherapeutic levels, 10 patients (15.2%) at therapeutic levels, and no patients with supratherapeutic levels.

Palabras llave : Magnesium sulphate; serum levels; therapeutic levels; toxicity; infratherapeutics; anticonvulsant prophylaxis.